Neurophet, a medical AI imaging company, said it has received preliminary approval from the Korea Exchange for a listing on the Kosdaq on Thursday, marking a key step in its plan to go public.

The company will now prepare a securities registration statement and begin the full-fledged process of an initial public offering (IPO). Mirae Asset Securities is the lead underwriter.

Founded in 2016, Neurophet specializes in the development of artificial intelligence-powered brain imaging analysis software and therapeutic medical devices. Its core technology enables ultra-fast, precision mapping of individual brain structures using AI, overcoming limitations of traditional neuroimaging in both diagnostics and treatment.

The company’s growth comes amid rising global attention to Alzheimer’s disease and the emergence of anti-amyloid therapies such as Eisai and Biogen’s lecanemab, marketed as Leqembi. Notably, the use of MRI and PET imaging for diagnosis, treatment eligibility, and safety monitoring has become a focal point in dementia care.

Neurophet has launched Neurophet AQUA AD, a software platform designed to assess patients’ eligibility for Alzheimer’s therapies, monitor therapeutic efficacy, and detect amyloid-related imaging abnormalities, or ARIA, a key side effect associated with anti-amyloid drugs. The solution is already being applied in real-world clinical settings.

Neurophet is also participating in clinical trials for new Alzheimer’s therapies. Since last year, the company has been conducting neuroimaging analysis projects in partnership with AriBio, a Korean biopharmaceutical firm developing investigational dementia treatments. Neurophet plans to expand into the companion diagnostics market based on these collaborations.

The company’s major offerings include Neurophet AQUA for neurodegeneration imaging analysis, Neurophet SCALE PET for PET scan quantification, Neurophet tES LAB for brain stimulation treatment planning, and Neurophet innk, a transcranial electrical stimulation device.

All of its core products have been certified by the Ministry of Food and Drug Safety, while both AQUA and SCALE PET have secured U.S. FDA 510(k) clearance. Neurophet also holds regulatory certifications from the EU, Japan, Singapore, and Thailand, which will support its accelerated push into global markets.

“Neurophet is solidifying its position as a leader in the full spectrum of brain disease management, from diagnosis to treatment,” Neurophet co-CEO Been Jun-kil said. “With the preliminary approval for our Kosdaq listing now secured, we will thoroughly prepare for our IPO and steadily advance toward long-term growth.”